Radioimmunotherapy with alpha-emitting nuclides

Michael R. McDevitt, George Sgouros, Ronald D. Finn, John L. Humm, Joseph G. Jurcic, Steven M. Larson, David A. Scheinberg

Research output: Contribution to journalReview article

Abstract

This review discusses the application of alpha particle-emitting radionuclides in targeted radioimmunotherapy. It will outline the production and chemistry of astatine-211, bismuth-212, lead-212, actinium-225, bismuth-213, fermium-255, radium-223 and terbium-149, which at present are the most promising alpha-emitting isotopes available for human clinical use. The selective cytotoxicity offered by alpha particle-emitting radioimmunoconstructs is due to the high linear energy transfer and short particle path length of these radionuclides. Based upon the pharmacokinetics of alpha particle-emitting radioimmunoconstructs, both stochastic and conventional dosimetric methodology is discussed, as is the preclinical and initial clinical use of these radionuclides conjugated to monoclonal antibodies for the treatment of human neoplasia.

Original languageEnglish (US)
Pages (from-to)1341-1351
Number of pages11
JournalEuropean Journal of Nuclear Medicine
Volume25
Issue number9
DOIs
StatePublished - Oct 12 1998
Externally publishedYes

Keywords

  • Actinium-225
  • Alpha particle-emitting radionuclides
  • Astatine-211
  • Bismuth-212
  • Bismuth-213
  • High linear energy transfer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Radioimmunotherapy with alpha-emitting nuclides'. Together they form a unique fingerprint.

  • Cite this

    McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., & Scheinberg, D. A. (1998). Radioimmunotherapy with alpha-emitting nuclides. European Journal of Nuclear Medicine, 25(9), 1341-1351. https://doi.org/10.1007/s002590050306